Moderna and Novavax grapple with COVID-19 vaccine supply hiccups overseas: reports

Halfway through the pandemic's second year, vaccine rollouts have hit their stride in some countries. Still, manufacturing problems can take an immediate toll on production and delivery timelines. Now, two COVID-19 vaccines—one authorized and the other not—are grappling with delays overseas. Moderna and Novavax are facing separate struggles to supply their COVID-19 shots outside the U.S., according to media reports and company representatives. For one, a South Korean shipment of Moderna’s authorized mRNA vaccine will now arrive in August instead of late July, thanks to issues with two of the biotech’s European manufacturing partners, Reuters reports.